Biotech firms continue to push the boundaries in gene editing and bispecific antibody engineering. UK-based Forge Genetics secured £2 million to develop a novel gene editing platform as an alternative to CRISPR, targeting bacterial strains with plans for human and animal applications. Meanwhile, Cartography Biosciences closed a $67 million Series B round to advance T cell engagers designed to treat colorectal cancer. Furthermore, Alligator Bioscience and Lund University developed a bispecific antibody simultaneously targeting CD40 and tumor antigen CEACAM5 for colorectal carcinoma. These advancements represent cutting-edge modalities aiming to improve therapeutic specificity and efficacy in cancer and infectious disease.